Your cells from today are the hope of tomorrow
Umbilical Cord Blood (UCB) is a source rich in hematopoietic stem cells, which give rise to blood and immune system cells. These cells represent today a valuable therapeutic resource for the treatment of hematologic and metabolic diseases. In addition, inside the Umbilical Cord blood there are, although in a lesser proportion, mesenchymal stem cells and endothelial stem cells, which are being used in clinical research for the development of cell therapies. Nowadays, stem cells from the Umbilical Cord blood can be applied in the treatment of over 70 diseases. Also, in the past few years, many clinical trials that could extend their use have emerged.
One of the main reasons to consider their cryopreservation is that they are compatible with the baby, so there is no risk of rejection. On the other hand, there is a high probability of them turning out compatible with a first degree relative, turning their protection into a family investment.
The vision of our company is to improve quality of life by using stem cells, which is why at Bioss Células Madre our Chemists, Biologists and Biotechnologists have specialized training in the cell separation process, granted by the creators of this technology. We also have Medical Directors specialized in Hematology, highly trained in hematopoietic progenitor stem cell transplants, as well as in the extraction and handling of bone marrow stem cells, which allows us to stay at the forefront and offer our customers more than one option. At Bioss Células Madre® we are committed to quality; that is why during our safeguard process of the sample we follow the guidelines of the Foundation for the Accreditation of Cellular Therapy (FACT-NETCORD), because we understand that we are protecting a future hope in the life of your children or even of your family.
Frequently Asked Questions
These are cells that have the ability of differentiation, self-renewal and proliferation, i.e., they can give rise to specialized cells with different types of tissue; they can divide to produce more stem cells, and they can do it indefinitely. These features make Stem Cells ideal for regenerative therapies.
• The UCB collection process is a noninvasive procedure and has no risks to either the mother or the newborn. • It is an immediately available source of stem cells* • Consolidated treatment for some hematologic and metabolic diseases. • Less probability of developing GVHD (graft versus host disease) as they are “immunologically immature” • Its use does not generate any ethical problem as it is a source of adult stem cells. *For HLA compatible patients
Some of the advantages we can offer are:
- We are a private institution that is governed by its own criteria, as we do not belong to any franchise.
- The processing and storage is carried out within our facilities.
- We are backed by the Federal Commission for the Protection Against Health Risks.
- Our separation processes are fully automated and in closed systems (SEPAX ®).
- Our storage system consists in cryogenic bags which are protected with a second quarantine bag.
- Samples are frozen under liquid nitrogen vapor, which prevents any type of cross-contamination among them.
We have strict security systems such as: access control through fingerprint systems to the laboratory and safeguarding areas, 24/7 monitoring system, electricity backup equipment, electricity plant.
It is a simple and painless process for both the mother and the baby. Collection of the UCB can be carried out if the delivery is vaginal or cesarean. Once the baby is born, the gynecologist makes the area where the puncture will be performed aseptic and inserts the needle that accompanies the collection bag; the UCB flows by gravity into the collection bag (the gynecologist must be very careful to remove as much UCB as possible and obtain a volume suitable for further processing – at least 40 mL); after extracting the UCB, the bag is sealed and marked for its shipment to our facilities.
The laboratory staff performs an initial assessment in which they evaluate: the collected volume and the number of initial cells; with these data we can give you a preliminary report by telephone about the results of your sample. After finishing all laboratory tests, in a span of 45 days, you will receive a detailed report with the amount of stem cells obtained and the results of laboratory studies.
So far there is no “expiration or maturity date.” There are studies of the first UCB bank, Bank of New York (New York Blood Center), which indicate that the cryopreservation of cord blood units for over 20 years is feasible; these samples have the same biological properties with which they were initially cryopreserved.
Cells can be used by any member of the family who is genetically compatible with the sample. There is a 25% probability of being HLA identical in first degree family members.
This is known by performing histocompatibility (HLA) studies. During the processing of the sample, different UCB vials are cryopreserved at the same time; this will allow us to perform these studies in the future without disturbing the sample.